SUTRO BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
SUTRO BIOPHARMA, INC. (STRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $6.08 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-23
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $3.67, a 71.42% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $5.72, a 62.19% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $13.21, a 132.16% increase year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $12.84, a 129.29% increase year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $6.08, a 80.21% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $30.73, a 700.26% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.84, a 23.66% decline from fiscal 2022.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.03, a 64.68% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $6.08 10-K · filed 2026-03-23 | ||||
| 2024-12-31 | $30.73 10-K · filed 2026-03-23 | $3.07 10-K · filed 2025-03-13 | |||
| 2023-12-31 | $3.84 10-K · filed 2025-03-13 | ||||
| 2022-12-31 | $5.03 10-K · filed 2025-03-13 | ||||
| 2022-06-30 | $3.67 10-Q · filed 2022-08-08 | $5.02 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $5.72 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $14.24 10-K · filed 2024-03-25 | ||||
| 2021-09-30 | $13.21 10-Q · filed 2021-11-10 | $14.35 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $12.84 10-Q · filed 2022-08-08 | $14.71 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $15.13 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | $5.59 10-K · filed 2023-03-30 | ||||
| 2020-09-30 | $5.69 10-Q · filed 2021-11-10 | $5.09 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $5.60 10-Q · filed 2021-08-09 | $5.03 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $4.94 10-Q · filed 2021-05-07 | ||||
| 2019-12-31 | $6.71 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $4.88 10-Q · filed 2020-11-05 | $6.74 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $6.79 10-Q · filed 2020-08-06 | $6.97 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $5.86 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | $9.48 10-K · filed 2021-03-18 | ||||
| 2018-09-30 | $8.93 10-Q · filed 2019-11-08 | $8.93 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | $8.21 10-Q · filed 2019-08-14 | ||||
| 2018-03-31 | $8.39 10-Q · filed 2019-05-15 | ||||
| 2017-12-31 | $7.26 10-K · filed 2020-03-16 | ||||
| 2017-09-30 | $7.20 10-Q · filed 2018-11-14 | $7.14 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $7.62 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |